title: Importance of bone assessment and prevention of osteoporotic fracture in patients with prostate cancer in the gonadotropic hormone analogues use.
abstract: The antiandrogenic therapy (ADT) for prostate cancer represents an additional risk factor for the development of osteoporosis and fragility fractures. Still, bone health of patients on ADT is often not evaluated. After literature research we found that simple preventive measures can prevent bone loss in these patients, resulting in more cost-effective solutions to the public health system and family when compared to the treatment of fractures.
authors.affiliation: Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
authors.forename: Bruno Lopes
authors.initials: BL
authors.lastname: Cançado
authors.affiliation: Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
authors.forename: Luiz Carlos
authors.initials: LC
authors.lastname: Miranda
authors.affiliation: Departament of Endocrinology, Faculty of Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
authors.forename: Miguel
authors.initials: M
authors.lastname: Madeira
authors.affiliation: Departament of Endocrinology, Faculty of Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
authors.forename: Maria Lucia Fleiuss
authors.initials: ML
authors.lastname: Farias
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D058866:Osteoporotic Fractures / Q000139:chemically induced* / Q000517:prevention & control*; D011471:Prostatic Neoplasms / Q000188:drug therapy*
chemical_list: D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone